Related Experiment Video
Updated: Jun 10, 2025
19:15
Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
85.8K
Clonidine as Monotherapy for Neonatal Opioid Withdrawal Syndrome: A Randomized Trial
Henrietta S Bada1, Philip M Westgate2, Thitinart Sithisarn1
1Department of Pediatrics, College of Medicine.
Pediatrics
|October 15, 2024
Summary
Clonidine effectively treats neonatal opioid withdrawal syndrome (NOWS) with similar treatment length and neurobehavioral outcomes as morphine. However, more infants treated with clonidine required adjunct therapy, indicating a need for dosage optimization.
Area of Science:
- Neonatal care
- Pharmacology
- Pediatric neurology
Background:
- Neonatal opioid withdrawal syndrome (NOWS) is a growing concern.
- Non-opioid pharmacotherapies are being investigated for NOWS treatment.
Purpose of the Study:
- To evaluate the efficacy of clonidine, a non-opioid α-2-adrenergic agonist, in treating NOWS.
- To compare clonidine with morphine for NOWS management.
Main Methods:
- An intention-to-treat randomized clinical trial.
- 120 infants with prenatal opioid exposure were randomized to oral clonidine or morphine.
- Primary outcomes included treatment duration and neurobehavioral performance.
Main Results:
- Treatment length was similar between clonidine and morphine groups (17 vs. 15 days).
- Neurobehavioral scores did not differ significantly post-treatment.
- 45% of clonidine-treated infants required adjunct therapy compared to 10% in the morphine group.
Conclusions:
- Clonidine is an effective non-opioid option for NOWS treatment.
- Treatment duration and neurobehavioral outcomes were comparable to morphine.
- Further research is needed to optimize clonidine dosage and minimize adjunct therapy use.
Related Concept Videos
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
237
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
237
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
149
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
149
01:17Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
176
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
176
01:25Analgesia and Pain Management
540
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
540